Patents by Inventor Rowan Kuiper

Rowan Kuiper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240327923
    Abstract: The present invention refers to a marker set for determining a PCL-like transcriptomic status in a sample which is indicative for a disease. Further, a method for determining a PCL-like transcriptomic status in a sample is provided by the present invention. In addition, the marker set and/or the method of the present invention is used for selecting an active agent for use in the treatment and/or prevention of a disease. In addition, the present invention refers to kits comprising means for determining the PCL-like transcriptomic status based on the marker set in a sample.
    Type: Application
    Filed: August 5, 2022
    Publication date: October 3, 2024
    Inventors: Davine Hofste Op Bruinink, Rowan Kuiper, Pieter Sonneveld
  • Publication number: 20210010091
    Abstract: This disclosure is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The disclosure also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the disclosure provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying the patient into a high risk or a low risk category, based on a 92-gene classifier.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Inventors: Rowan Kuiper, Pieter Sonneveld
  • Patent number: 10815532
    Abstract: This disclosure is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The disclosure also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the disclosure provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92-gene classifier.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 27, 2020
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Rowan Kuiper, Pieter Sonneveld
  • Publication number: 20180237866
    Abstract: This disclosure is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The disclosure also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the disclosure provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92-gene classifier.
    Type: Application
    Filed: April 23, 2018
    Publication date: August 23, 2018
    Inventors: Rowan Kuiper, Pieter Sonneveld
  • Patent number: 9976185
    Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: May 22, 2018
    Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
    Inventors: Rowan Kuiper, Pieter Sonneveld
  • Publication number: 20140221313
    Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.
    Type: Application
    Filed: July 12, 2012
    Publication date: August 7, 2014
    Applicant: Erasmus University Medical Center Rotterdam
    Inventors: Rowan Kuiper, Pieter Sonneveld